公司法律调查 - 律师事务所Glancy Prongay & Murray LLP宣布对aTyr Pharma Inc (NASDAQ: ATYR) 可能违反联邦证券法的行为展开调查 [1] - 调查旨在代表投资该公司的投资者进行 [1] - 调查与9月15日发生的事件相关 [1]

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of aTyr Pharma Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATYR PHARMA INC. (ATYR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at h. ...

法律行动 - Portnoy Law Firm告知aTyr Pharma投资者可针对2025年1月16日至2025年9月12日期间购买证券的行为提起集体诉讼 [1] - 投资者提交首席原告动议的截止日期为2025年12月8日 [1] 临床试验结果 - 2025年9月15日aTyr公布其efzofitimod用于肺结节病的三期EFZO-FIT™研究顶线结果 该试验涉及268名患者 [3] - 试验未能达到其主要终点 此消息导致公司股价在2025年9月15日盘中大幅下跌 [3]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ATyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ATyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/atyr-pharma-inc-loss-submission-form/?id=172042&from=4 CLASS PERIOD: January 16, 2025 to September 12, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of aTyr Pharma Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATYR PHARMA INC. (ATYR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On September 15, 2025, aTyr announced that the Phase 3 study of its intrav. ...

集体诉讼案件基本信息 - 罗森律师事务所宣布，代表在2025年1月16日至2025年9月12日期间（含起止日）购买aTyr Pharma公司普通股的购买者，提起集体诉讼 [1] - 集体诉讼已经提起，希望作为首席原告的投资者必须在2025年12月8日前向法院提出动议 [1][3] 诉讼指控内容 - 指控被告向投资者提供了过于积极的陈述，同时传播虚假和误导性陈述及/或隐瞒重大不利事实，涉及药物Efzofitimod的疗效，特别是该药物使患者能够完全停止使用类固醇的能力 [5] - 诉讼声称，当真实情况进入市场后，投资者遭受了损失 [5] 律师事务所背景信息 - 罗森律师事务所专注于证券集体诉讼和股东派生诉讼，其在2017年被ISS证券集体诉讼服务评为和解数量第一 [4] - 该律所自2013年以来每年排名前四，已为投资者追回数亿美元，仅在2019年就为投资者确保了超过4.38亿美元 [4]

公司事件概述 - 律师事务所Faruqi & Faruqi正在调查aTyr Pharma Inc (NASDAQ: ATYR) 并提醒投资者关于针对该公司的联邦证券集体诉讼的截止日期为2025年12月9日 [1] - 诉讼指控公司及其高管违反了联邦证券法 发布了虚假和/或误导性陈述 和/或未能披露有关Efzofitimod疗效的重大不利事实 [3] 核心产品临床数据 - 在EFZO-FIT研究中 Efzofitimod在48周时未能显示每日平均口服皮质类固醇剂量的任何变化 5.0 mg/kg剂量组平均减少2.79mg 而安慰剂组减少3.52mg [4] - 接受5.0 mg/kg Efzofitimod治疗的患者中有52.6%实现了完全停用类固醇 安慰剂组为40.2% [4] 市场反应与影响 - aTyr Pharma发布EFZO-FIT研究结果后 其股价从9月12日收盘价6.03美元暴跌至9月15日收盘价1.01美元 跌幅达83.25% [4] - 据称公司的虚假和/或误导性陈述导致原告及其他股东以人为抬高的价格购买了aTyr的证券 [3]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In aTyr (ATYR) To Contact Him Directly To Discuss Their Options If you purchased or acquired aTyr common stock between January 16, 2025, and September 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bra ...

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR). Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/atyr-pharma-inc-loss-submission-form/?id=171674&from=3 CLASS PERIOD: January 16, ...